The tragedy of the pandemic coronavirus disease 2019(COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used formany years for the prophylaxis and therapy of malariaand autoimmune diseases, has been put forward as atreatment option.The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has beenshown to have antiviral effects in SARS, MERS, Ebola,and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?
|Numero di pagine||3|
|Stato di pubblicazione||Published - 2020|
All Science Journal Classification (ASJC) codes